Carboplatin plus epirubicin plus VP-16, concurrent ‘split course’ radiotherapy and adjuvant surgery for limited small cell lung cancer

Gridelli, Cesare; D’Aprile, Modesto; Curcio, Carlo; Brancaccio, L; Palmeri, Sergio; Comella, G.; Veltri, Enzo; Ferrante, G; Gentile, Maria Teresa; Rossi, Antonio; Arcangeli, Giorgio; Montella, Maurizio; Bianco, A. R.

doi:10.1016/0169-5002(94)90285-2

Cited by 8 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modern cisplatin-based chemotherapy was rarely used and different policies concerning integration of radiotherapy were chosen. Only one study has given a bimodal induction combining chemotherapy and radiotherapy, but the patient number finally operated on was too small to draw conclusions (Gridelli et al, 1994). The only randomized trial testing surgery following induction chemotherapy came from the Lung Cancer Study Group (LCSG).…”

Section: Discussionmentioning

confidence: 99%

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

Eberhardt¹,

et al. 1999

View full text Add to dashboard Cite

Summary Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twentythree of patients (72%) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable -one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (n = 21) is 52 months (30+ -75+). Median survival and 5-year survival rate of all patients are 36 months and 46%, in R0 patients 68 months and 63% (R0-IIB/IIIA/IIIB: not yet reached and 67%). This multimodality treatment including surgery proved highly effective with 100% local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

Eberhardt¹,

et al. 1999

View full text Add to dashboard Cite

show abstract

“…To further examine the predicted results, we check them using literature support, and list out the drugs which have been verified in the published papers (Table 5 ). Among the top ranked drugs, six drugs have been reported in the treatment of HD [ 43 – 48 ]; three drugs have been found to treat NSCLC [ 49 – 51 ]; the study of Butriptyline (DB09016) on AD has already been reported by Pani etc [ 52 ], and the clinical trial of drug Lorazepam (DB00186) on AD has already been done [ 53 ]; Carboplatin (DB00958), Irinotecan (DB00762), Doxorubicin (DB00997) and Epirubicin (DB00445) have already been studied to treat SCLC [ 54 – 58 ].…”

Section: Resultsmentioning

confidence: 99%

Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration

Liu

Wang

2017

BMC Med Genomics

View full text Add to dashboard Cite

BackgroundPrediction of drug-disease interactions is promising for either drug repositioning or disease treatment fields. The discovery of novel drug-disease interactions, on one hand can help to find novel indictions for the approved drugs; on the other hand can provide new therapeutic approaches for the diseases. Recently, computational methods for finding drug-disease interactions have attracted lots of attention because of their far more higher efficiency and lower cost than the traditional wet experiment methods. However, they still face several challenges, such as the organization of the heterogeneous data, the performance of the model, and so on.MethodsIn this work, we present to hierarchically integrate the heterogeneous data into three layers. The drug-drug and disease-disease similarities are first calculated separately in each layer, and then the similarities from three layers are linearly fused into comprehensive drug similarities and disease similarities, which can then be used to measure the similarities between two drug-disease pairs. We construct a novel weighted drug-disease pair network, where a node is a drug-disease pair with known or unknown treatment relation, an edge represents the node-node relation which is weighted with the similarity score between two pairs. Now that similar drug-disease pairs are supposed to show similar treatment patterns, we can find the optimal graph cut of the network. The drug-disease pair with unknown relation can then be considered to have similar treatment relation with that within the same cut. Therefore, we develop a semi-supervised graph cut algorithm, SSGC, to find the optimal graph cut, based on which we can identify the potential drug-disease treatment interactions.ResultsBy comparing with three representative network-based methods, SSGC achieves the highest performances, in terms of both AUC score and the identification rates of true drug-disease pairs. The experiments with different integration strategies also demonstrate that considering several sources of data can improve the performances of the predictors. Further case studies on four diseases, the top-ranked drug-disease associations have been confirmed by KEGG, CTD database and the literature, illustrating the usefulness of SSGC.ConclusionsThe proposed comprehensive similarity scores from multi-views and multiple layers and the graph-cut based algorithm can greatly improve the prediction performances of drug-disease associations.

show abstract

Surgery for limited-stage small-cell lung cancer

Barnes

See

Barnett

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Evidence from currently available RCTs does not support a role for surgical resection in the management of limited-stage small-cell lung cancer; however our conclusions are limited by the quality of the available evidence and the lack of contemporary data. The results of the trials included in this review may not be generalisable to patients with clinical stage 1 small-cell lung cancer carefully staged using contemporary staging methods. Although some guidelines currently recommend surgical resection in clinical stage 1 small-cell lung cancer, prospective randomised controlled trials are needed to determine if there is any benefit in terms of short- and long-term mortality and quality of life compared with chemo-radiotherapy alone.

show abstract

Carboplatin plus epirubicin plus VP-16, concurrent ‘split course’ radiotherapy and adjuvant surgery for limited small cell lung cancer

Cited by 8 publications

References 16 publications

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: Long-term results of a phase II trial

Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration

Surgery for limited-stage small-cell lung cancer

Contact Info

Product

Resources

About